Search

22 Feb 2023: 18 October 2018. Spin-out PredictImmune announces new patent grants and allowances in UK, EU, Canada.

4 Jul 2023: A wealth of training and networking opportunities are available within the University's entrepreneurial ecosystem in Cambridge.

22 Feb 2023: PharmEnable aims to develop new treatments for conditions with significant unmet clinical need by designing highly complex molecules for addressing challenging biological targets. ... We are pleased to welcome on board our new investors and appreciate

13 Dec 2023: The periods for which your data will be held will be provided to you in a new privacy notice.

22 Feb 2023: It’s a real pleasure to be working with a new company that we know to have an excellent pedigree.”.

17 Jan 2023: Share:. Cambridge researchers have developed a new test that ‘fishes’ for multiple respiratory viruses at once, using single strands of DNA as ‘bait’, and that gives highly accurate results in under ... This work elegantly uses new technology to

22 Feb 2023: Inotec AMD, a maker of mobile medical devices designed to heal chronic, hypoxic wounds, secures investment from Amadeus Capital Partners.

13 Dec 2023: Mobile menu. Mobile menu. Search. back. back. back. back. back. Making a Subject Access Request. Under data protection legislation an individual has the right, subject to certain exemptions, to access information from organisations that process

22 Feb 2023: benefits, as they provide ways to power sensors from ambient vibration, and permit the creation of new types of sensors with dramatically lower power consumption than before. ... This new capital will provide the resources to scale 8power’s engagement

5 Apr 2023: The funding round was oversubscribed and led by Mission Possible Capital, a new Swiss venture capital fund with founding partners who previously co-foundedand Redalpine Venture Partners. ... Nicolas Berg, Founding Partner, Mission Possible. Pause. Play.

22 Sep 2023: Share:. Industry specialists from across the continent came together to discover new technologies from four of the UK’s leading universities.

23 Feb 2023: This new funding will used to develop the manufactured version of Cyto-Mine and enable its commercial launch later this year. ... Craig. “This new instrument can accelerate and enable the discovery of diverse antibodies from primary cells and find high

1 Aug 2023: Mobile menu. Mobile menu. Search. back. back. back. back. back. How we use your personal information – Cambridge Enterprise Venture Partners. How we use your personal information – Cambridge Enterprise Venture Partners. This policy is intended

24 Aug 2023: Zero. As part of this drive, Cambridge Enterprise will invest up to £10 million in 15 new businesses addressing a key subset of the United Nations Sustainable Development Goals. ... We continue to build, support and follow our Sustainability portfolio

1 Nov 2023: The new Space Ranger 9100 will be on show at the RFID Journal Live! ... Tags:Image: Guangzhou, China - April 22, 2016: A HM Store in Guangzhou seen from the outside in Zhujiang new town(downtown Guangzhou).

23 Feb 2023: Xampla holds two patents for the new material, with a third in development. ... With our new plant protein material, we are committed to helping manufacturers make the transition from traditional plastics to high performance alternatives that protect the

22 Feb 2023: Share:. Psyomics Ltd, a UK-based healthtech and University of Cambridge spin-out, has closed a £1.5 million funding round from existing and new investors to bring its mental health

22 Feb 2023: Richard Pugh, Investor, BGF and new Board member for Echion. This partnership is part of our global strategy to accelerate the time to market of our Battery Materials Business front and ... We are optimistic and believe that these new products will be

21 Nov 2023: Adam Workman, Head of Investments & New Ventures, Oxford University Innovation.

22 Feb 2023: This latest round of investment is a great recognition of our success to date, with new and existing investors confirming the strength of our technology.